B-cell malignancy-derived cell lines
. | Oncogenic events . | Phenotype/genotype . | References . |
|---|---|---|---|
| Precursor B ALL | |||
| V9 (murine) | v-ABL | NA | Gurish et al, 199517 |
| 70Z (murine) | Nitrosourea-induced | NA | Paige et al, 197818 |
| WEHI231 (murine) | Mineral oil–induced | NA | Ralph, 197924 |
| 697 | E2A-PBX1, BCL2, MYC | Relapsed, t(1;19), del(6)(q21), CALLA | Findley et al, 198225 |
| Nalm-6 | TEL-PDGFRB | Relapsed, t(5;12), CALLA | Hurwitz et al, 197926 |
| JM-1 | BCL2 | CALLA | NA |
| JIM | NA | NA | NA |
| Hodgkin | |||
| L428 | NA | Refractory, hypertetraploid | Schaadt et al, 198021 |
| Myeloma | |||
| RPMI-8226 | NA | Triploid, 14q+, 22q-, lambda+, EBV- | Matsuoka et al, 196727 |
| NCI-H929 | cellular MYC, RAS | Relapsed, 8q+, kappa+, EBV- | Gazdar et al, 198028 |
| U266 | BCL2 | Refractory, 11q13, IgE, lambda, IL6+ | Nilsson et al, 197029 |
| Biphenotypic MLL | |||
| SEM-K2 | MLL-AF4 | Relapsed, t(4;11), CD19+/CD13+ | Pocock et al, 199522 |
| RS4;11 | MLL-AF4 | Relapsed, t(4;11), i(7q) | Stong et al, 198523 |
. | Oncogenic events . | Phenotype/genotype . | References . |
|---|---|---|---|
| Precursor B ALL | |||
| V9 (murine) | v-ABL | NA | Gurish et al, 199517 |
| 70Z (murine) | Nitrosourea-induced | NA | Paige et al, 197818 |
| WEHI231 (murine) | Mineral oil–induced | NA | Ralph, 197924 |
| 697 | E2A-PBX1, BCL2, MYC | Relapsed, t(1;19), del(6)(q21), CALLA | Findley et al, 198225 |
| Nalm-6 | TEL-PDGFRB | Relapsed, t(5;12), CALLA | Hurwitz et al, 197926 |
| JM-1 | BCL2 | CALLA | NA |
| JIM | NA | NA | NA |
| Hodgkin | |||
| L428 | NA | Refractory, hypertetraploid | Schaadt et al, 198021 |
| Myeloma | |||
| RPMI-8226 | NA | Triploid, 14q+, 22q-, lambda+, EBV- | Matsuoka et al, 196727 |
| NCI-H929 | cellular MYC, RAS | Relapsed, 8q+, kappa+, EBV- | Gazdar et al, 198028 |
| U266 | BCL2 | Refractory, 11q13, IgE, lambda, IL6+ | Nilsson et al, 197029 |
| Biphenotypic MLL | |||
| SEM-K2 | MLL-AF4 | Relapsed, t(4;11), CD19+/CD13+ | Pocock et al, 199522 |
| RS4;11 | MLL-AF4 | Relapsed, t(4;11), i(7q) | Stong et al, 198523 |
E2A-PBX1 indicates early region 2a-pre-B-cell leukemia transcription factor 1; MYC, pre-B-cell leukemia transcription factor 1; CALLA, common acute lymphoblastic leukemia antigen; TEL-PDGFRB, translocated ets leukemia-platelet-derived growth factor receptor β; EBV, Epstein-Barr virus; IgE, immunoglobulin E; IL6, interleukin-6; MLL-AF4, mixed-lineage leukemia–ALL1 fused gene from chromosome 4; and NA, not available.